Sun Pharma settles row with Novartis over cancer drug

Sun Pharma settles row with Novartis over cancer drug

FPJ BureauUpdated: Saturday, June 01, 2019, 12:50 PM IST
article-image

New Delhi

Sun Pharma has inked a settlement pact with Novartis Pharmaceutical Corporation over cancer drug Gleevec, paving the way for the Indian drug major to launch a generic version of the medicine in the US market in 2016.

One of the subsidiaries of Sun Pharma has executed a settlement agreement with Novartis, stipulating a dismissal of the lawsuits filed in the United States against the company regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gleevec, the Indian drug major said in a statement.

“Under the terms of the settlement agreement, Sun Pharma’s subsidiary may launch its version of generic Gleevec in the United States on February 1, 2016,” it added. The other terms of the agreement are confidential, the Mumbai-based firm said, adding that the agreement is subject to customary regulatory approvals. Sun Pharma’s subsidiary holds a tentative approval from the US Food and Drug Administration for its ANDA for a generic version of Gleevec.

As per IMS sales data, Gleevec had annual sales of around $2 billion in the US. Gleevec, which is the registered trademark of Novartis, is indicated for the treatment of chronic myeloid leukemia. Sun Pharmaceutical has a first-to-file status for generic Gleevec that entitles it to sell the generic version exclusively for the first six months after launch.

RECENT STORIES

JioBlackRock Gets SEBI Nod To Launch 4 More Funds, Adds Equity And G-Sec Index Schemes

JioBlackRock Gets SEBI Nod To Launch 4 More Funds, Adds Equity And G-Sec Index Schemes

Markets End Marginally Higher, Global Cues & Tariff Worries Weigh On Sentiment

Markets End Marginally Higher, Global Cues & Tariff Worries Weigh On Sentiment

RBI Adopts Wait & Watch Stance On Rate Cuts, Governor Malhotra Stresses Balance Between Growth &...

RBI Adopts Wait & Watch Stance On Rate Cuts, Governor Malhotra Stresses Balance Between Growth &...

Cabinet Approves PM Dhan-Dhaanya Krishi Yojana In Big Push To Agriculture Sector

Cabinet Approves PM Dhan-Dhaanya Krishi Yojana In Big Push To Agriculture Sector

India's Electric Car Ecosystem To Cross 7% Penetration by FY28, Sales Rise 20x in Three Years

India's Electric Car Ecosystem To Cross 7% Penetration by FY28, Sales Rise 20x in Three Years